Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kesten, S.
Right arrow Articles by Rich, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kesten, S.
Right arrow Articles by Rich, S.
(Chest. 1999;116:566-569.)
© 1999 American College of Chest Physicians

Development of Nonspecific Interstitial Pneumonitis Associated With Long-term Treatment of Primary Pulmonary Hypertension With Prostacyclin*

Steven Kesten, MD, FCCP; John Dainauskas, MD; Vallerie McLaughlin, MD and Stuart Rich, MD, FCCP

* From the Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL.

Correspondence to: Steven Kesten, MD, FCCP, Rush-Presbyterian-St. Luke's Medical Center, 1725 W. Harrison St, Suite 836, Chicago, IL 60612; e-mail: skesten{at}rush.edu

A young woman with primary pulmonary hypertension presented with interstitial lung disease approximately 5 years after successful treatment with IV prostacyclin. The pathology was consistent with nonspecific interstitial pneumonitis and was unresponsive to steroids and immunosuppressive medications. We speculate that further cases of this syndrome may be reported as more patients are living beyond 5 years with prostacyclin.

Key Words: interstitial lung disease • primary pulmonary hypertension • prostacyclin




This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
H. Morimatsu, K. Goto, T. Matsusaki, H. Katayama, H. Matsubara, T. Ohe, and K. Morita
Rapid Development of Severe Interstitial Pneumonia Caused by Epoprostenol in a Patient with Primary Pulmonary Hypertension
Anesth. Analg., October 1, 2004; 99(4): 1205 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
A. Resten, S. Maitre, M. Humbert, A. Rabiller, O. Sitbon, F. Capron, G. Simonneau, and D. Musset
Pulmonary Hypertension: CT of the Chest in Pulmonary Venoocclusive Disease
Am. J. Roentgenol., July 1, 2004; 183(1): 65 - 70.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Archer and S. Rich
Primary Pulmonary Hypertension : A Vascular Biology and Translational Research "Work in Progress"
Circulation, November 28, 2000; 102(22): 2781 - 2791.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Chest Physicians.